• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 164
  • 73
  • 29
  • 24
  • 8
  • 7
  • 6
  • 6
  • 5
  • 3
  • 2
  • 2
  • 1
  • 1
  • Tagged with
  • 386
  • 169
  • 125
  • 64
  • 61
  • 58
  • 55
  • 51
  • 48
  • 47
  • 45
  • 44
  • 39
  • 39
  • 36
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
41

Design and evaluation of lipid based delivery systems for delivery of small molecules and macro-molecular nucleotides based therapeutic agents

Pan, Xiaogang. January 2006 (has links)
Thesis (Ph. D.)--Ohio State University, 2006. / Full text release at OhioLINK's ETD Center delayed at author's request
42

Fluorometric sedimentation equilibrium for lipoprotein sub-class analysis.

Henriquez, Ronald Rene 15 May 2009 (has links)
Fluorometric density gradient ultracentrifugation is used to measure the lipoprotein density profile for cardiovascular disease risk assessment. The work presented establishes the effectiveness of using a single-spin separation as both an analytical tool and a preparative tool, while yielding valuable density information. This research expands on the analytical power of density gradient ultracentrifugation (DGU) by combining novel ethylenediaminetetraacetic acid (EDTA) gradient solutions, a fluorescent probe for analysis, and modern statistical methods for classification of heart disease risk. Sub-classes of lipoproteins are analyzed based on their density from the fluorescent lipoprotein density profile. The application of linear discriminant analysis (LDA) and sliced average variance estimation (SAVE) to the fluorometric DGU data yields a powerful classification tool. This method is capable of determining differences between control and cardiovascular disease patients that do not exhibit the traditional risk factors. The combination of these methods has great potential to serve as analytical tools for researchers in understanding the mechanisms of disease development and as a diagnostic tool for clinicians.
43

Cloning of lipid metabolism-related genes LPL and FABPs of cobia (Rachycentron canadum) and their mRNA expressions as affected by dietary fatty acid composition

Tseng, Mei-Cheuh 22 August 2008 (has links)
The present study cloned successfully two lipid-metabolism genes, lipoprotein lipase (LPL) and fatty acid binding protein (FABPs) from cobia and studied the mRNA expressions of the two genes and their upstream gene PPARs when the cobia were fed diets containing 15% lipid. Among the lipids, 6% was fish oil and the remaining 9% were supplemented by fish oil (FO, rich in n-3 HUFA), perilla oil (PE, rich in 18:2 n-6), safflower oil (SA, rich in 18:2 n-6), olive oil (OL, rich in 18:1 n-9) or palm oil (PA, rich in 16:0). The whole sequences of LPL, liver-FABP (L-FABP) and muscle-FABP (M-FABP) encode 520, 126 and 133 amino acids, respectively. RT-PCR and real time PCR analyses based on these gene sequences show that the mRNA expressions of L-FABP and M-FABP in the tissue of the cobia were diet-specific. The mRNA expression of LPL, on the other hand, did not respond to the treatments, except in visceral fat depot. Linear regression analysis shows that the mRNA expression of LPL in the liver and muscle was positively (P<0.05) related to dietary fatty acids and ther concentration, but that in the visceral fat depot was negatively related. The mRNA expression of FABPs was also positively correlated with dietary fatty acid levels. Among all fatty acids, the levels of C14:0, C20:1 n-9, EPA and DHA were positively correlated with the mRNA expression of PPAR£^and also with FABPs mRNA expression in the visceral fat depot and LPL mRNA expression in the muscle. Thus, LPL, L-FABP and M-FABP mRNA expression of the cobia were highly influenced by the kind and amount of dietary fatty acids. The role of PPARs was not clearly demonstrated.
44

Variants in the lipoprotein lipase gene and paraoxonase gene and risk of preeclampsia /

Zhang, Cuilin. January 2003 (has links)
Thesis (Ph. D.)--University of Washington, 2003. / Vita. Includes bibliographical references (leaves 82-89).
45

Physical activity and high -density lipoprotein cholesterol in sedentary male smokers

Shaw, BS, Shaw, I 16 December 2007 (has links)
High-density lipoprotein (HDL) with its cardio- protective effects has provided remarkable optimism to the ever-increasing incidences of coronary artery disease. Therefore, the aim of this randomized, comparative, research trial was to determine whether endurance exercise training, weight training and/or a combination of aerobic and weight training can be utilized in the management of high-density lipoprotein cholesterol (HDL-C). Subsequent to the 16-week intervention period, dependant t-Tests revealed that the non-exercising and weight training groups demonstrated non- significant mean 1.3% (p = 0.754) and 11.1% (p = 0.069) increases in fasting serum HDL-C, respectively. Conversely, there was a significant increase in HDL-C following the 16 weeks of endurance training (p = 0.003) and combination training (p = 0.005) (22.4% and 37.9%, respectively). Further, Spearman’s rho indicated no correlations between HDL-C and BMI (r = -0.131), percentage body fat (r = - 0.141), cholesterol intake (r = - 0.026) and total fat intake (r = - 0.239). The absence of changes in these inter-correlations indicated that changes in these parameters had no effect on the HDL-C. On the contrary, moderate correlations were established between HDL-C and number of cigarettes smoked daily (r = - 0.344) and intake of saturated fat (r = - 0.317) indicating that exercise effect on these variables could have indirectly contributed significantly in altering HDL- C in the endurance and combination training groups. As such, endurance and combination training can be utilized as an effective method in the management of HDL-C in sedentary male smokers.
46

Lipoprotein(a) and myocardial infarction in South Asians

Haycock, Philip Charles January 2013 (has links)
No description available.
47

Tid- och temperaturoptimering av lipoproteinlipas-aktivitet : -   en studie på Soleus och Vastus lateralis hos möss / Time-and temperature-optimization of lipoprotein lipase-activity

Ådemo, Ida January 2012 (has links)
No description available.
48

BIOACTIVE FATTY ACID SUPPLEMENTATION AND RISK FACTORS FOR THE METABOLIC SYNDROME

Mitchell, Patricia 06 August 2010 (has links)
Diet plays an important role in the development of chronic metabolic diseases (diabetes, obesity, cardiovascular disease) and as dietary fat consumption has increased, so has the incidence of these disorders. Metabolic syndrome, a clustering of risk factors that includes central obesity, increased plasma triacylglycerol (TG), elevated fasting glucose and glucose intolerance is perhaps the most notorious and aggressive. Animal and human studies indicate that bioactive fatty acids can influence cellular energy metabolism. Using susceptible rodent models (apoE-/- and LDLr-/- mice and Syrian Golden hamsters) this project investigated whether supplementation of a western type diet (WD) with bioactive fatty acids could improve hepatic lipid metabolism, plasma lipoprotein profiles or liver markers of lipogenesis. In mice, dietary supplementation with t-10, c-12 conjugated linoleic acid (CLA) decreased the weight gain induced by high fat diet compared with WD (p<0.01) and was accompanied by hyperinsulinemia (p<0.05) in the ApoE-/- and hypoadiponectinemia (p<0.01) in both mice strains. Although t-10, c-12 CLA supplementation increased plasma lipids and was associated with profound liver steatosis there was a reduction in atherosclerotic lesions in both mouse models (p<0.05). Analysis of mRNA and protein levels in the liver suggested that the differences in liver and plasma lipids may reflect inappropriate lipogenic response to t-10,c-12 CLA. In the high fat and fructose-fed hamster, the modulating role of fish fatty acids was investigated. The addition of DHA increased weight gain and adiposity compared to EPA and c-9, t-11 CLA supplementation. However, glucose tolerance was improved after 6 weeks of DHA supplementation (p? 0.01). Using [35S]methionine radiolabelling, DHA supplementation decreased apolipoprotein B100 synthesis and secretion. Newly synthesized cellular and secreted TG, as measured by [3H]glycerol incorporation, were also decreased with DHA supplementation. Although the effects of EPA were similar to those with DHA, the magnitude was generally lower. These results suggest that supplementation with fish fatty acids can improve several of the risk factors of the metabolic syndrome. Taken together, these observations indicate that some, but not all, bioactive fatty acids may be useful supplements for mediating cardiovascular risk factors.
49

EFFECTS OF Apolipoprotein(a) ON VASCULAR ENDOTHELIAL CELL FUNCTION: INSIGHTS INTO POSSIBLE PHYSIOLOGICAL AND/OR PATHOLOGICAL ROLES FOR Lipoprotein(a)

LIU, LEI 25 September 2009 (has links)
Numerous studies have identified that elevated plasma concentrations of lipoprotein(a) [Lp(a)] are an emerging risk factor for a variety of atherothrombotic disorders. Apolipoprotein(a) [apo(a)], the unique glycoprotein component of Lp(a), consists of tandem repeats of a plasminogen kringle (K) IV-like domain, followed by sequences homologous to the plasminogen KV and protease domains. Apo(a)/Lp(a) has been consistently shown to regulate endothelial function and inhibit plasminogen activation. In the present study, we have demonstrated that apo(a), signaling via integrin alphaVbeta3, is the functional unit in Lp(a) to stimulate in vitro endothelial cell (EC) proliferation and migration, and activate focal adhesion kinase (FAK) and mitogen-activated protein kinases (MAPK) in cultured ECs. Both apo(a) and Lp(a) have also been shown to reduce the levels of active and total transforming growth factor (TGF)-beta in cultured EC medium in an integrin alphaVbeta3–dependent manner. Despite the stimulatory effects of apo(a) on EC proliferation and migration, we have further confirmed an inhibitory effect of apo(a) on EC in vitro angiogenesis using a fibrin gel tube formation assay. We have provided evidence proving apo(a) inhibits angiogenesis through inhibition of plasminogen activation, and this inhibitory effect is dependent on the presence of apo(a) KV domain. Lastly, apo(a) is shown to reduce the protein levels of annexin A2 and S100A10 in ECs, which implies another potential mechanism by which apo(a)/Lp(a) could impair plasminogen activation on cell surface. In summary, we have discovered the first complete outside-in signaling pathway elicited by apo(a)/Lp(a) in ECs and have built up a connection between the ability of apo(a) to inhibit plasminogen activation and its inhibition of angiogenesis. / Thesis (Ph.D, Biochemistry) -- Queen's University, 2009-09-25 18:29:47.106
50

Characterisation, Recombinant Expression and Immunogenicity of BHLP29.7, An Outer Membrane Lipoprotein of Brachyspira Hyodysenteriae

T.La@murdoch.edu.au, Tom La January 2006 (has links)
Swine dysentery (SD) is an important endemic infection in many piggeries, and control can be problematic. In this study, the gene encoding a 29.7 kDa outer membrane lipoprotein of the causative intestinal spirochaete Brachyspira hyodysenteriae, was identified and sequenced. An 816 bp hypothetical open reading frame (ORF) was identified, with a potential ribosome binding site, and putative –10 and –35 promoter regions upstream from the start of the ORF. The 29.7 kDa outer membrane lipoprotein was designated Bhlp29.7 and the encoding gene named bhlp29.7. The amino acid sequence of Bhlp29.7 included a 19 residue hydrophobic signal peptide, incorporating a potential signal peptidase cleavage site and membrane lipoprotein lipid attachment site. In silico analysis of this protein together with lipidation studies further supported its probable outer membrane localisation. Comparison of the Bhlp29.7 sequence with public sequence databases showed that it had up to 40% similarity with the D-methionine substrate-binding outer membrane lipoprotein (MetQ) of a number of bacterial pathogens. The Bhlp29.7 gene was detected in all 48 strains of B. hyodysenteriae examined, and in Brachyspira innocens strain B256T, but not in 10 other strains of B. innocens or in 42 strains of other Brachyspira spp. The gene was sequenced from B. innocens strain B256T and from 11 strains of B. hyodysenteriae. The B. hyodysenteriae genes shared 97.9-100% nucleotide sequence identity and had 97.5-99.5% identity with the gene of B. innocens strain B256T. The Bhlp29.7 gene was subsequently cloned and expressed as a histidine fusion protein in an Escherichia coli expression system. An ELISA test using recombinant his-tagged Bhlp29.7 (His6-Bhlp29.7) as the detecting antigen was developed and evaluated. The threshold value of the test was chosen to provide a highly stringent assessment of the disease status of a herd. The sensitivity and specificity of the test was 100%. When the test was applied to sera from eight herds with suspected SD, four gave ELISA values indicating that the herds were diseased. The remaining four herds gave ELISA values below the threshold value. These results indicated that the Bhlp29.7-ELISA was useful as an indirect test for exposure of a herd to B. hyodysenteriae and may be a helpful complement to current methods of SD diagnosis. Recombinant His6-Bhlp29.7 was evaluated as a vaccine subunit for prevention of SD. The His6-Bhlp29.7 was shown to be immunogenic in mice following two intramuscular injections. Vaccination of mice with His6-Bhlp29.7 provided full protection after oral challenge with B. hyodysenteriae. In two experiments, intramuscular and oral vaccination of pigs with the His6-Bhlp29.7 resulted in a 50% reduction in incidence of SD compared to unvaccinated control pigs (P=0.047). This is the first subunit vaccine shown to provide pigs with protection from SD. Further work is needed to optimise delivery routes and adjuvants for commercial development of the vaccine.

Page generated in 0.0674 seconds